The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome.
L KuhlwilmCarlos Schönfeldt-LecuonaM GahrB J ConnemannF KellerAlexander SartoriusPublished in: Acta psychiatrica Scandinavica (2020)
An overall superiority of the specific NMS therapy (dantrolene, bromocriptine, and ECT) was not found in this study. When regarding severity classification, specific therapies were superior but only in severe cases, and ECT showed the lowest mortality rate. In previous case series, an effect on survival or the duration of the disease could only be observed in part for specific therapies, but the evidence available is inconsistent. The results of this study support our hypothesis that NMS treatment with dantrolene, bromocriptine, and ECT is advantageous over purely symptomatic therapy in severe NMS cases.